Original Research
Published on 24 Apr 2025
Impact of primary cancer history and molecular landscape in therapy-related myeloid neoplasms
in Hematologic Malignancies
Frontiers in Oncology
doi 10.3389/fonc.2025.1563990
- 247 views
Type at least 3 characters
1,829 articles
Case Report
Accepted on 22 Apr 2025
Cord blood therapy for pure red cell aplasia after allogeneic hematopoietic stem cell transplantation: case series and review
in Hematologic Malignancies
Frontiers in Oncology
doi 10.3389/fonc.2025.1585088
- 108 views
Original Research
Accepted on 22 Apr 2025
Efficacy and safety of blinatumomab in Chinese patients with relapsed/refractory B-cell acute lymphoblastic leukemia: a single-center retrospective study
in Hematologic Malignancies
Frontiers in Oncology
doi 10.3389/fonc.2025.1587185
- 100 views
Original Research
Accepted on 22 Apr 2025
Efficacy and Safety of Pegylated Interferon in the Treatment of JAK2 V617F -Positive Polycythemia Vera with a Dose De-escalation Strategy: A Single-Center Retrospective Study
in Hematologic Malignancies
Frontiers in Oncology
doi 10.3389/fonc.2025.1586839
- 102 views
Original Research
Accepted on 22 Apr 2025
Impact of CD3 Expression on Outcome in Pediatric Anaplastic Large Cell Lymphoma
in Hematologic Malignancies
Frontiers in Oncology
doi 10.3389/fonc.2025.1569370
Review
Published on 22 Apr 2025
Targeting BCL2 in Waldenström macroglobulinemia: from biology to treatment management
in Hematologic Malignancies
Frontiers in Oncology
doi 10.3389/fonc.2025.1564869
- 508 views
Original Research
Accepted on 21 Apr 2025
Hematological cancer patients’ social support, coping strategies, anxiety, depression and posttraumatic growth: A structural equation model
in Hematologic Malignancies
Frontiers in Oncology
doi 10.3389/fonc.2025.1540973
Original Research
Accepted on 21 Apr 2025
Divergent gene expression of PTGS1 and PTGS2 along the disease course of chronic myeloid leukaemia
in Hematologic Malignancies
Frontiers in Oncology
doi 10.3389/fonc.2025.1556956
Case Report
Accepted on 21 Apr 2025
Sclerosing Variant of Extramedullary Hematopoietic Tumor Primary arising in Kidney, Unexpected Clinical and Pathological Presentation
in Hematologic Malignancies
Frontiers in Oncology
doi 10.3389/fonc.2025.1573784
Correction
Accepted on 17 Apr 2025
Corrigendum: Liposomes have a direct effect on multiple myeloma: A Mendelian randomization study
in Hematologic Malignancies
Frontiers in Oncology
doi 10.3389/fonc.2025.1603501
- 116 views
Review
Accepted on 17 Apr 2025
The biology of Chronic Myeloid Leukemia: an overview of the new insights and biomarkers
in Hematologic Malignancies
Frontiers in Oncology
doi 10.3389/fonc.2025.1546813
Original Research
Accepted on 15 Apr 2025
Impact of Secondary Hematologic Malignancies on Prognosis of Hodgkin’s Lymphoma Survivors
in Hematologic Malignancies
Frontiers in Oncology
doi 10.3389/fonc.2025.1566063
Original Research
Accepted on 14 Apr 2025
CD38 prognostic role in chronic lymphocytic leukemia patients treated with standard chemotherapy or targeted agents: a monocentric real-life experience
in Hematologic Malignancies
Frontiers in Oncology
doi 10.3389/fonc.2025.1569707
- 142 views
Systematic Review
Published on 14 Apr 2025
Atopic dermatitis and lymphoma risk: a systematic review and meta-analysis
in Hematologic Malignancies
Frontiers in Oncology
doi 10.3389/fonc.2025.1580550
- 504 views
Original Research
Accepted on 11 Apr 2025
Analysis of Pharmacotherapeutic Approaches for Multiple Myeloma and Correlated Renal and Pulmonary Impairments: A Retrospective Real-World Registry Study in the Greater Gulf Region (REPAIR Study)
in Hematologic Malignancies
Frontiers in Oncology
doi 10.3389/fonc.2025.1547138
- 308 views
Case Report
Accepted on 09 Apr 2025
Venetoclax combined with ATRA shows promising therapeutic potential for TFG::RARA variant APL：a case report
in Hematologic Malignancies
Frontiers in Oncology
doi 10.3389/fonc.2025.1529640